{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:39:55Z","timestamp":1791585595002,"version":"4.3.4"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,11,15]]},"DOI":"10.2169\/internalmedicine.3032-19","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T22:03:29Z","timestamp":1562709809000},"page":"3267-3271","source":"Crossref","is-referenced-by-count":10,"title":["Synchronous Occurrence of Bazex Syndrome and Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Patient with Lung Cancer"],"prefix":"10.2169","volume":"58","author":[{"given":"Yoichiro","family":"Aoshima","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"},{"name":"Department of Clinical Oncology, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sagisaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Juzen Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yasui","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironao","family":"Hozumi","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bazex A, Griffiths A. Acrokeratosis paraneoplastica - a new cutaneous marker of malignancy. Br J Dermatol 103: 301-306, 1980.","DOI":"10.1111\/j.1365-2133.1980.tb07248.x"},{"key":"2","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1001\/jama.1985.03360190069027","volume":"254","author":"DJ McCarty","year":"1985","unstructured":"2. McCarty DJ, O'Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema: RS3PE syndrome. JAMA 254: 2763-2767, 1985.","journal-title":"JAMA The Journal of the American Medical Association","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chung VQ, Moschella SL, Zembowicz A, Liu V. Clinical and pathologic findings of paraneoplastic dermatoses. J Am Acad Dermatol 54: 745-762, 2006.","DOI":"10.1016\/j.jaad.2004.06.051"},{"key":"4","unstructured":"4. Karabulut AA, Sahin S, Sahin M, Ek\u015fio\u011flu M, Ust\u00fcn H. Paraneoplastic acrokeratosis of Bazex (Bazex's syndrome): report of a female case associated with cholangiocarcinoma and review of the published work. J Dermatol 33: 850-854, 2006."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. R\u00e4\u00dfler F, Goetze S, Elsner P. Acrokeratosis paraneoplastica (Bazex syndrome) - a systematic review on risk factors, diagnosis, prognosis and management. J Eur Acad Dermatol Venereol 31: 1119-1136, 2017.","DOI":"10.1111\/jdv.14199"},{"key":"6","unstructured":"6. Sibilia J, Friess S, Schaeverbeke T, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis? J Rheumatol 26: 115-120, 1999."},{"key":"7","unstructured":"7. Oliv\u00e9 A, del Blanco J, Pons M, Vaquero M, Tena X. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catal\u00e1n Group for the Study of RS3PE. J Rheumatol 24: 333-336, 1997."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Suzuki K, Shiono S, Hayasaka K, Yarimizu K, Endoh M, Yanagawa N. A surgical case of minimally invasive adenocarcinoma associated with remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome. Jpn J Lung Canc 58: 105-110, 2018.","DOI":"10.2482\/haigan.58.105"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis 64: 1653-1655, 2005.","DOI":"10.1136\/ard.2004.032995"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hamanaka R, Murakami S, Yokose T, Nakayama H, Yamada K, Iwazaki M. Lung cancer associated with remitting seronegative symmetrical synovitis with pitting edema-like features. Jpn J Lung Canc 51: 253-258, 2011.","DOI":"10.2482\/haigan.51.253"},{"key":"11","unstructured":"11. Origuchi T, Arima K, Kawashiri S, et al. Nine cases of remitting seronegative symmetrical synovitis with pitting edema syndrome complicated with malignancies. Clin Rheumatol 24: 206-214, 2012."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Medsger TA, Dixon JA, Garwood VF. Palmar fasciitis and polyarthritis associated with ovarian carcinoma. Ann Intern Med 96: 424-431, 1982.","DOI":"10.7326\/0003-4819-96-4-424"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Manger B, Schett G. Palmar fasciitis and polyarthritis syndrome - Systematic literature review of 100 cases. Nat Rev Rheumatol 44: 105-111, 2014.","DOI":"10.1016\/j.semarthrit.2014.03.005"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Iwanami K, Nakai M, Kitamura K. Bazex syndrome. Intern Med 57: 1501-1502, 2018.","DOI":"10.2169\/internalmedicine.9771-17"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis 64: 1653-1655, 2005.","DOI":"10.1136\/ard.2004.032995"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833, 2016.","DOI":"10.1056\/NEJMoa1606774"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33: 2004-2012, 2015.","DOI":"10.1200\/JCO.2014.58.3708"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Metro G, Ricciuti B, Brambilla M, et al. The safety of nivolumab for the treatment of advanced non-small cell lung cancer. Expert Opin Drug Saf 16: 101-109, 2017.","DOI":"10.1080\/14740338.2017.1267725"},{"key":"19","unstructured":"19. Califano R, Lal R, Lewanski C, et al. Patient selection for anti-PD-1\/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future Oncol 14: 2415-2431, 2018."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Leonardi GC, Gainor JF, Altan M, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36: 1905-1912, 2018.","DOI":"10.1200\/JCO.2017.77.0305"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/22\/58_3032-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T03:45:55Z","timestamp":1573875955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/22\/58_3032-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":20,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3032-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]}}}